| Bioactivity | AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1[1]. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants[2]. |
| Target | TLR7/TLR8 |
| Name | AXC-715 trihydrochloride |
| CAS | 2479276-17-8 |
| Formula | C18H28Cl3N5 |
| Molar Mass | 420.81 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1. [2]. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1. |
AXC-715 trihydrochloride
CAS: 2479276-17-8 F: C18H28Cl3N5 W: 420.81
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1. AXC-715 trihydrochlo
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.